tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BioMarin price target lowered to $96 from $97 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $96 from $97 and keeps an Overweight rating on the shares. The firm notes in an earnings preview that for Q2 its estimates are in line with the Street on revenues, but further out its sees BioMarin having under-appreciated revenue potential.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1